BioLineRx/$BLRX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About BioLineRx
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
- Ticker
- $BLRX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 22
- Headquarters
- Hevel Modi'in, Israel
- Website
- www.biolinerx.com
BioLineRx Metrics
BasicAdvanced
$9.4M
-
-$0.00
0.70
-
Price and volume
Market cap
$9.4M
Beta
0.7
52-week high
$3.95
52-week low
$1.45
Average daily volume
13K
Financial strength
Current ratio
1.195
Quick ratio
1.009
Long term debt to equity
0.191
Total debt to equity
0.478
Interest coverage (TTM)
-12.01%
Profitability
EBITDA (TTM)
-12.118
Gross margin (TTM)
80.03%
Net profit margin (TTM)
-502.08%
Operating margin (TTM)
-874.28%
Revenue per employee (TTM)
$60,000
Management effectiveness
Return on assets (TTM)
-19.82%
Return on equity (TTM)
-55.27%
Valuation
Price to revenue (TTM)
2,838.095
Price to book
1.9
Price to tangible book (TTM)
-10.26
Price to free cash flow (TTM)
-364.571
Free cash flow yield (TTM)
-0.27%
Free cash flow per share (TTM)
-0.004
Growth
Revenue change (TTM)
-91.93%
Earnings per share change (TTM)
-40.19%
3-year earnings per share growth (CAGR)
-62.32%
10-year earnings per share growth (CAGR)
-35.94%
BioLineRx Financial Performance
Revenues and expenses
BioLineRx Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.